摘要
目的比较盐酸文拉法辛缓释片联合舒肝解郁胶囊与单用盐酸文拉法辛缓释片治疗伴躯体症状抑郁症的效果及安全性。方法选择符合《中国精神障碍分类与诊断标准(第3版)》(CCMD-3)的抑郁症伴躯体症状患者60例,按就诊时间和入院顺序单双号分为研究组和对照组各30例。两组均服用盐酸文拉法辛缓释片,研究组在此基础上加用舒肝解郁胶囊治疗,疗程6周,在治疗第2、4、6周对患者进行汉密顿抑郁量表17项版(HAMD-17)及副反应量表(TESS)评定。结果治疗第6周末,研究组显效率高于对照组(86.67%vs.73.33%,χ2=6.125,P<0.05);两组HAMD-17评分差异有统计学意义[(7.36±3.41)vs.(11.14±3.25),t=4.59,P<0.01];两组HAMD-17焦虑/躯体化因子评分差异有统计学意义[(4.64±1.11)vs.(1.57±1.45),t=6.324,P<0.01];两组TESS评分差异无统计学意义[(3.47±0.85)vs.(3.96±1.23),t=1.12,P>0.05]。结论盐酸文拉法辛缓释片联合舒肝解郁胶囊治疗伴躯体症状抑郁症较单用盐酸文拉法辛缓释片起效更快,更快改善躯体症状,不增加药物的不良反应。
Objective To compare the effect and safety of veulafaxine sustained- release tablet combined with Shuganjieyu capsule and venlafaxine sustained- release tablet used singlely in the treatment of depression with somatic symptoms. Methods 60 patients suffered from depression with somatic symptoms were randomly divided into two groups,30 cases in each group. The patients in the control group were only treated with veulafaxine sustained- release tablet,and the patients in the study group were treated with venlafaxine sustained- release tablet combined with Shuganjieyu capsule. The treatment lasted 6 weeks. All patients were evaluated with Hamilton Depression Scale- 17 item( HAMD- 17) and Treatment Emergent Symptom Scale( TESS) at the 2nd,4th,6thweek of the treatment. Results After treatment for 6 weeks,excellence rate of the study group was significantly higher than the control group( 86. 67% vs. 73. 33%,χ2= 6. 125,P < 0. 05). There were statistically significant between the two groups in the scores of HAMD- 17[( 7. 36 ± 3. 41) vs.( 11. 14 ± 3. 25),t = 4. 59,P < 0. 01]. Significant differences in factor scores of anxiety somatization in HAMD- 17 were found between two groups[( 4. 64 ± 1. 11) vs.( 1. 57 ± 1. 45),t = 6. 324,P < 0. 01]. The difference of TESS scores between two groups was not significant[( 3. 47 ± 0. 85) vs.( 3. 96 ± 1. 23),t = 1. 12,P > 0. 05]. Conclusion Venlafaxine sustained- release tablet combined with Shuganjieyu capsule is effective and safe in the treatment of depression with somatic symptoms,and takes effects quicker and improves somatizations more significantly than veulafaxine sustained- release tablet.
出处
《四川精神卫生》
2015年第4期327-330,共4页
Sichuan Mental Health
关键词
伴躯体症状的抑郁症
文拉法辛缓释片
舒肝解郁胶囊
Depression with somatic symptoms
Veulafaxine sustained-release tablet
Shuganjieyu capsule
